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Abstract
Various antidepressants are commonly used for the treatment of depression and several other neuropsychiatric disorders. In
addition to their primary effects on serotonergic or noradrenergic neurotransmitter systems, antidepressants have been
shown to interact with several receptors and ion channels. However, the molecular mechanisms that underlie the effects of
antidepressants have not yet been sufficiently clarified. G protein-activated inwardly rectifying K
+ (GIRK, Kir3) channels play
an important role in regulating neuronal excitability and heart rate, and GIRK channel modulation has been suggested to
have therapeutic potential for several neuropsychiatric disorders and cardiac arrhythmias. In the present study, we
investigated the effects of various classes of antidepressants on GIRK channels using the Xenopus oocyte expression assay.
In oocytes injected with mRNA for GIRK1/GIRK2 or GIRK1/GIRK4 subunits, extracellular application of sertraline, duloxetine,
and amoxapine effectively reduced GIRK currents, whereas nefazodone, venlafaxine, mianserin, and mirtazapine weakly
inhibited GIRK currents even at toxic levels. The inhibitory effects were concentration-dependent, with various degrees of
potency and effectiveness. Furthermore, the effects of sertraline were voltage-independent and time-independent during
each voltage pulse, whereas the effects of duloxetine were voltage-dependent with weaker inhibition with negative
membrane potentials and time-dependent with a gradual decrease in each voltage pulse. However, Kir2.1 channels were
insensitive to all of the drugs. Moreover, the GIRK currents induced by ethanol were inhibited by sertraline but not by
intracellularly applied sertraline. The present results suggest that GIRK channel inhibition may reveal a novel characteristic of
the commonly used antidepressants, particularly sertraline, and contributes to some of the therapeutic effects and adverse
effects.
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Introduction
Depression is one of the most common illnesses in the world
[1,2]. After the efficacy of tricyclic antidepressants (TCAs),
including imipramine, amitriptyline and amoxapine, was well
established, various classes of antidepressants were introduced,
including selective serotonin reuptake inhibitors (SSRIs; fluoxe-
tine, paroxetine and sertraline), serotonin-norepinephrine reup-
take inhibitors (SNRIs; venlafaxine and duloxetine), selective
norepinephrine reuptake inhibitors (NRIs; reboxetine), noradren-
ergic and specific serotonergic antidepressants (NaSSAs; mirtaza-
pine and mianserin), and 5-hydroxytryptamine type 2 (5-HT2)
receptor antagonists (nefazodone) [1–3]. Antidepressants are
commonly used for the treatment of depression and several
neuropsychiatric disorders, such as anxiety disorders, eating
disorders, obsessive-compulsive disorders, and chronic pain
disorders [1–3]. Their clinical efficacy is hypothesized to be linked
mainly with facilitation of noradrenergic or serotonergic function
in the brain [2]. In contrast, the interaction between antidepres-
sants and muscarinic, a1 adrenergic, and H1 histamine receptors is
involved in some of their adverse side effects, such as dry mouse,
orthostatic hypotension, and sedation [2]. Antidepressants have
also been shown to modulate the function of several other
receptors and ion channels, including 5-HT2C and 5-HT3
receptors, nicotinic acetylcholine receptors, N-methyl-D-aspartate
(NMDA) receptor channels, P2X2 receptors, voltage-gated Ca
2+,
Na
+, and K
+ channels, Ca
2+-activated K
+ channels, two-pore-
domain K
+ channels, and volume regulated anion channels
[4–23]. The modulation of these receptors and channels might
also be relevant to the pharmacological effects of antidepressants.
However, the molecular mechanisms that underlie the effects of
various antidepressants have not yet been sufficiently clarified.
G protein-activated inwardly rectifying K
+ (GIRK) channels
(also known as Kir3 channels) are members of a major subfamily
of inwardly rectifying K
+ (Kir) channels that includes seven sub-
families [24]. Four GIRK channel subunits have been identified in
mammals [25–27]. Neuronal GIRK channels are predominantly
heterotetramers composed of GIRK1 and GIRK2 subunits in
most brain regions or homotetramers composed of GIRK2
subunits in the substantia nigra [27–30], whereas atrial GIRK
channels are heterotetramers composed of GIRK1 and GIRK4
subunits [26]. The channels are activated by various Gi/o-protein-
coupled receptors, such as M2 muscarinic, a2 adrenergic, D2
dopaminergic, opioid, nociceptin/orphanin FQ, CB1 cannabi-
noid, and A1 adenosine receptors, through the direct action of G-
protein bc subunits [31–33]. Additionally, ethanol activates GIRK
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[34,35]. GIRK channels play an important role in regulating
neuronal excitability, synaptic transmission, and heart rate [31,36–
39]. Furthermore, recent studies have suggested that GIRK
channel modulation has the potential for treating several
neuropsychiatric disorders and cardiac arrhythmias [33,40,41].
Therefore, GIRK channel modulators may affect various brain
and cardiac functions. We have demonstrated the distinctive
effects of several antidepressants on GIRK channels, even among
the same class, particularly SSRIs [42,43]. To further clarify the
interaction between various classes of commonly used antidepres-
sants and GIRK channels may be useful for advancing our
understanding of the pharmacological effects of antidepressants. In
the present study, we examined the effects of various antidepres-
sants on GIRK channels using the Xenopus oocyte expression assay.
Materials and Methods
Preparation of specific mRNAs
Plasmids that contain the entire coding sequences for the mouse
GIRK1, GIRK2, and GIRK4 channel subunits were obtained
previously [34,44,45]. cDNAs for mouse Kir2.1 in pcDNA1 [46]
were generously provided by Dr. Lily Y. Jan (University of
California, San Francisco). These plasmids were linearized by
digestion with the appropriate enzymes as described previously
[45,46]. The specific mRNAs were synthesized in vitro using the
mMESSAGE mMACHINE
TM In Vitro Transcription Kit (Am-
bion, Austin, TX, USA).
Electrophysiological analysis
Adult female Xenopus laevis frogs (Copacetic, Soma, Aomori, Japan)
were anesthetized by immersion in water that contained 0.15%
tricaine (Sigma-Aldrich, St. Louis, MO, USA). A small incision was
madeontheabdomentoremoveseveralovarianlobesfromthefrogs,
which were humanely killed after the final collection. All procedures
for the care and treatment of animals were performed in accordance
with National Institutes of Health guidelines and were approved by
the Institutional Animal Care and Use Committee of Niigata
University(PermitNumber:172-2).Xenopusoocytes(StagesVandVI)
were manually isolated from the ovary and maintained in Barth’s
solution [47]. Oocytes were injected with mRNA for GIRK1/
GIRK2 or GIRK1/GIRK4 combinations (0.15 ng each) or Kir2.1
(0.3 ng). The oocytes were incubated at 19uC in Barth’s solution and
manually defolliculated after treatment with 0.8 mg/ml collagenase
(Wako Pure Chemical Industries, Osaka, Japan) for 1 h. The whole-
cell currents of the oocytes were recorded from 3 to 9 days after
injection with a conventional two-electrode voltage clamp [34,48].
The membrane potential was held at 270 mV unless otherwise
specified. Microelectrodes were filled with 3 M KCl. The oocytes
were placed in a 0.05 ml narrow chamber and continuously
superfused with a high-potassium (hK) solution (96 mM KCl,
2m MN a C l ,1m MM g C l 2, 1.5 mM CaCl2 and 5 mM HEPES,
pH 7.4 with KOH) or a K
+-free high-sodium (ND98) solution
(98 mM NaCl, 1 mM MgCl2, 1.5 mM CaCl2 and 5 mM HEPES,
pH 7.4 with NaOH) at a flow rate of 2.5 ml/min. In the hK solution,
the K
+ equilibrium potential was close to 0 mV, and the inward K
+
current flow through the Kir channels was observed at negative
holding potentials as previously shown [25,27,43]. Additionally, to
examine the effects of antidepressants on outward K
+ currents, a
p e r f u s i o ns o l u t i o nt h a tc o n t a i n e d4m MK
+ (K4 solution) was made
by substituting NaCl with KCl in the ND98 solution. To examine the
effects of an antidepressant on GIRK channels activated by G-
protein activation, 13.8 nl of 100 mM Li4-guanosine-59-O-(3-thio-
triphosphate) (GTPcS; Sigma-Aldrich), a nonhydrolyzable G-protein
activator, dissolved in distilled water was injected into an oocyte using
a nanoliterinjector (World PrecisionInstruments, Sarasota,FL, USA)
as described previously [49]. Furthermore, to examine the effects of
intracellularsertraline,23 nlof10 mMsertraline dissolvedindistilled
water was injected into an oocyte using a Nanoliter injector as
described previously [50], and the oocyte currents were then
continuously recorded for approximately 30–40 min. Because the
volume of the Xenopus oocytes used was approximately 1 ml, the
intracellular concentration of sertraline was presumed to be
approximately 225 mM. For the analysis of concentration-response
relationships, the data were fitted to a standard logistic equation [51]
using KaleidaGraph (Synergy Software, Reading, PA, USA). The
concentration of a drug that produces 50% of the maximal current
response for that drug (EC50), the concentrations required to reduce
control currents by 25% and 50% (IC25 and IC50, respectively), and
the Hill coefficient (nH) were obtained from the concentration-
response relationships.
Data analyses
The data are expressed as mean 6 SEM, and n is the number of
oocytes tested. The statistical analysis of differences between
groups was performed using paired t-test, one-way analysis of
variance (ANOVA), or two-way ANOVA followed by the Tukey-
Kramer post hoc test. Values of P,0.05 were considered statistically
significant.
Compounds
All of the antidepressants tested were commercially purchased.
Amoxapine and nefazodone hydrochloride were obtained from
Sigma-Aldrich. Mirtazapine and mianserin hydrochloride were
obtained from Tocris Bioscience (Bristol, UK). Sertraline hydro-
chloride and duloxetine hydrochloride were obtained from Tronto
Research Chemicals (North York, Canada). Venlafaxine hydro-
chloride was obtained from LKT Laboratories (St. Paul, MN,
USA). Sertraline was dissolved in dimethyl sulfoxide (DMSO) or
distilled water, and venlafaxine was dissolved in distilled water.
The other antidepressants were dissolved in DMSO. The stock
solution of each compound was stored at 230uC until use. Ethanol
was purchased from Wako Pure Chemical Industries. Each
compound was added to the perfusion solution in appropriate
amounts immediately before the experiments.
Results
Inhibition of GIRK channels by antidepressants
In Xenopus oocytes injected with GIRK1 and GIRK2 mRNAs,
basal GIRK currents, which depend on free G-protein bc subunits
present in the oocytes because of the inherent activity of G-
proteins [32], were observed at a holding potential of 270 mV in
an hK solution that contained 96 mM K
+ (Fig. 1A). The 3 mM
Ba
2+-sensitive current components (1042.8690.1 nA, n=30)
correspond to the magnitude of GIRK currents in oocytes that
express GIRK channels [34]. Extracellular application of 30 mM
sertraline, an SSRI, reversibly reduced the inward currents
through the expressed GIRK channels (Fig. 1A). The current
responses to an additional 100 mM sertraline during the appli-
cation of 3 mM Ba
2+, which blocks Kir channels, were not
significant (reduction of inward currents by 4.563.5 nA; less than
1% inhibition of the Ba
2+-sensitive current components, n=4).
Sertraline at 100 mM produced no significant response in a K
+-
free ND98 perfusion solution that contained 98 mM Na
+ instead
of the hK solution (3.061.8 nA, n=4), suggesting that the SSRI-
sensitive current components show K
+ selectivity. Additionally, the
application of DMSO or distilled water, the solvent vehicles, at the
GIRK Channel Inhibition by Antidepressants
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response in the hK or ND98 solutions (n=5; data not shown).
In contrast, in oocytes injected with mRNA for Kir2.1, a
constitutively active Kir channel [46], extracellular application of
300 mM sertraline had no significant effect on the inward currents
through the channels in the hK solution (less than 2% change of
the Ba
2+-sensitive current components; 848.36322.0 nA, n=4;
Fig. 1B). In uninjected oocytes, 300 mM sertraline and 3 mM Ba
2+
caused no significant response (2.062.0 nA, n=4, and
3.161.7 nA, n=4, respectively; Fig. 1C) compared with oocytes
injected with GIRK mRNA, suggesting no significant effect of
sertraline or Ba
2+ on intrinsic oocyte channels. Furthermore, in
oocytes injected with GIRK1 and GIRK4 mRNAs, 30 mM
sertraline similarly inhibited basal GIRK currents under the same
conditions (51.664.3% inhibition of 3 mM Ba
2+-sensitive current
components, 561.7658.2 nA, n=11). Additionally, the Ba
2+-
sensitive current components in oocytes injected with mRNA for
GIRK1/GIRK2 or GIRK1/GIRK4 combinations were very
significantly larger than those in oocytes injected with the same
small amount of a single GIRK mRNA (less than 20 nA, n=7,
respectively). The results indicate that sertraline predominantly
inhibited GIRK1/2 and GIRK1/4 heteromultimeric channels,
but not Kir2.1 channels. Moreover, the effects of different classes
of antidepressants on GIRK channels were examined using the
same expression assay. Amoxapine, a second generation TCA,
and duloxetine, an SNRI, significantly inhibited basal GIRK
currents at 100 mM (45.664.4 and 65.661.0% inhibition for
GIRK1/2, n=5 and 7, respectively; 27.664.0 and 49.762.2%
inhibition for GIRK1/4, n=4 and 6, respectively). However, the
5-HT2 receptor antagonist nefazodone, NaSSAs mianserin and
mirtazapine, and SNRI venlafaxine weakly inhibited the currents
at 100 mM (35.963.5, 24.165.5, 17.663.5, and 19.464.6%
inhibition for GIRK1/2, n=11, 4, 4, and 4, respectively;
30.363.4, 18.861.3, 12.162.4, and 22.863.2% inhibition for
GIRK1/4, n=13, 5, 5, and 5, respectively). Additionally, the
inhibitions were reversible with washout, similar to sertraline (data
not shown). In contrast, Kir2.1 channels were insensitive to these
drugs at 100 mM (less than 4% change of the Ba
2+-sensitive
current components; 912.56182.8 nA, n=4). In uninjected
oocytes, 300 mM of the drugs caused no significant response (less
than 6 nA; n=4 for each of the drugs). Altogether, the results
suggest significant inhibition of GIRK channels by sertraline,
duloxetine, and amoxapine, weak inhibition of the channels by
nefazodone, mianserin, mirtazapine, and venlafaxine, and no
significant effects of the drugs on Kir2.1 channels.
Concentration-dependent inhibition of GIRK channels by
various antidepressants
The concentration-response relationships for the inhibitory
effects of different classes of antidepressants on GIRK1/2
and GIRK1/4 channels were investigated. Figure 2 shows that
the inhibitions of both types of GIRK channels by various
antidepressants were concentration-dependent with distinctive
potency and effectiveness at micromolar concentrations. The rank
order of the inhibition of GIRK channels by 100 mM of these
drugs was the following: duloxetine$sertraline.amoxapine.ne-
fazodone.mianserin$venlafaxine<mirtazapine for GIRK1/2
channels and sertraline.duloxetine&nefazodone, amoxapine.
venlafaxine, mianserin.mirtazapine for GIRK1/4 channels.
Table 1 shows the EC50 and nH values obtained from the
concentration-response relationships for sertraline, duloxetine and
amoxapine, and the percentage inhibition of the GIRK currents
by the drugs at the highest concentrations tested. Additionally,
because the drugs could not completely block these types of GIRK
channels even at the highest concentrations tested, the IC25 and
IC50 values were also calculated to further compare the effects of
the drugs (Table 1). The inhibition of GIRK1/2 channels by
sertraline was similar to that by duloxetine (Fig. 2). Furthermore,
the inhibition of GIRK1/2 channels by sertraline was statistically
similar to the inhibition of GIRK1/4 channels (P.0.05 at each
concentration, Tukey-Kramer post hoc test; Fig. 2, Table 1). In
contrast, the inhibition of GIRK1/2 channels by duloxetine and
amoxapine was more effective than the inhibition of GIRK1/4
channels (P,0.05 at 30, 100, and 300 mM for duloxetine and
P,0.05 at 300, 500, and 1000 mM for amoxapine, Tukey-Kramer
post hoc test; Fig. 2, Table 1).
Characteristics of inhibition of GIRK channels by the SSRI
sertraline and SNRI duloxetine
Sertraline and duloxetine, which belong to commonly used
classes of antidepressants, effectively inhibited GIRK channels,
and we further investigated the effects of these drugs in more
detail. Instantaneous GIRK1/2 currents elicited by the voltage
step to 2100 mV from a holding potential of 0 mV were
diminished in the presence of 30 mM sertraline applied for
3 min (Fig. 3A). The percentage inhibition of the steady-state
GIRK current at the end of the voltage step by sertraline was not
significantly different from that of the instantaneous current
(P.0.05, paired t-test; n=9 at 240, 260, 280, 2100, and
2120 mV, respectively). For duloxetine, the instantaneous
currents were primarily diminished in the presence of 30 mM
duloxetine, and the currents gradually increased in the voltage step
(Fig. 3A). The percentage inhibition of the steady-state GIRK
current at the end of the voltage step by duloxetine significantly
decreased compared with that of the instantaneous current
(P,0.05 at 280, 2100 and 2120 mV, paired t-test, n=6).
Figure 3B shows that 30 mM sertraline- and duloxetine-sensitive
currents in oocytes that expressed GIRK1/2 channels increased
with negative membrane potentials, and the current-voltage
relationships showed strong inward rectification (n=9 and 6,
Figure 1. Inhibitory effects of sertraline on GIRK channels
expressed in Xenopus oocytes. (A) In an oocyte injected with GIRK1
and GIRK2 mRNAs, current responses to 30 mM sertraline and 3 mM
Ba
2+ are shown. (B) In an oocyte injected with Kir2.1 mRNA, current
responses to 100 mM sertraline and 3 mM Ba
2+ are shown. (C) In an
uninjected oocyte, no significant current responses to 300 mM sertraline
or 3 mM Ba
2+ are shown. Current responses were measured at a
membrane potential of 270 mV in an hK solution that contained
96 mM K
+. Asterisks show the zero current level. Horizontal bars
indicate the duration of application.
doi:10.1371/journal.pone.0028208.g001
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2+-sensitive currents that
corresponded to basal GIRK currents, indicating a characteristic
of GIRK currents. The percentage inhibition of GIRK1/2
currents by 30 mM sertraline at the end of the voltage pulses
showed no significant difference across voltages between 2120
and 240 mV (no significant sertraline effect6membrane potential
effect interaction, P.0.1, one-way ANOVA; P.0.1 across
voltages, Tukey-Kramer post hoc test; Fig. 3C), suggesting
voltage-independent inhibition of GIRK channels by sertraline.
In contrast, the GIRK current inhibition by duloxetine at the end
of the voltage pulses was voltage-dependent, with weaker
inhibition at more negative membrane potentials (significant
duloxetine effect6membrane potential effect interaction,
P,0.05, one-way ANOVA; significant differences between
2120 and 260 mV, between 2120 and 240 mV, between
2100 and 260 mV, and between 2100 and 240 mV, P,0.05,
Tukey-Kramer post hoc test, n=6, Fig. 3C). The voltage-
dependency was associated with a time-dependent decrease in
the inhibition by duloxetine in the voltage pulses at more negative
membrane potentials. Furthermore, similar results were obtained
in oocytes that expressed GIRK1/4 channels (n=4 for each of the
drugs; data not shown). Altogether, sertraline and duloxetine
primarily inhibited GIRK channels at the holding potential of
0 mV before the voltage pulses. The inhibitory effects of sertraline
were voltage-independent and time-independent during each
voltage pulse, whereas those of duloxetine decreased voltage-
dependently with negative membrane potentials and time-
dependently up to a steady state current level in each voltage
pulse.
Furthermore, the effects of the two antidepressants on GIRK
channels under a physiological K
+ condition were examined. In
oocytes injected with GIRK1 and GIRK2 mRNAs, outward
currents observed at a holding potential of 210 mV in a K4
solution that contained 4 mM K
+ were reversibly reduced by
30 mM sertraline (n=4), 30 mM duloxetine (n=4), and 3 mM Ba
2+
(the Ba
2+-sensitive current components, 49.062.8 nA, n=8; Fig.
S1), whereas in uninjected oocytes, the drugs at 100 mMa n d3m M
Ba
2+ caused no significant response (3.060.9 nA for sertraline,
060 nA for duloxetine, and 7.661.3 nA for Ba
2+; n=4 ,4 ,a n d8 ,
respectively). The results suggest that the antidepressants also
inhibited outward GIRK currents at a physiologically extracellular
K
+ concentration.
Sertraline and duloxetine possess a secondary amine group with
pKa values of 8.9 and 9.34, respectively (Data Sheets of Pfizer and
Figure 2. Concentration-response relationships for the effects
of various antidepressants on GIRK1/2 and GIRK1/4 channels.
The magnitudes of inhibition of GIRK currents by the drugs were
compared with the 3 mM Ba
2+-sensitive current components in oocytes
that expressed GIRK1/2 channels or GIRK1/4 channels (762.8636.0 nA,
n=50, and 585.0644.0 nA, n=40, respectively). Each point and error
bar represent the mean 6 SEM of the percentage responses.
doi:10.1371/journal.pone.0028208.g002
Table 1. Inhibitory effects of sertraline, duloxetine and amoxapine on GIRK channels.
Sertraline Duloxetine Amoxapine
GIRK1/2 GIRK1/4 GIRK1/2 GIRK1/4 GIRK1/2 GIRK1/4
EC50 (mM) 11.761.0 12.662.5 14.960.4 17.061.3 38.766.2 17.764.4
IC25 (mM) 6.960.6 7.061.0 6.660.6 12.661.2 21.568.3 39.7615.8
IC50 (mM) 29.163.4 36.767.8 28.362.5 124.2634.3 181.1648.3 ND
% max 73.762.9 63.763.5 72.261.1 54.161.5 58.962.9 36.061.6
(mM; n) (500; 16) (300; 11) (300; 7) (300; 6) (1000; 5) (1000; 4)
nH 1.0260.05 0.8960.09 0.9460.06 0.9760.07 0.8760.03 0.8760.07
Mean 6 SEM concentrations of antidepressants (mM) that produce 50% of the maximal effect (EC50) and are required to reduce basal GIRK currents by 25% and 50%
(IC25 and IC50, respectively) are shown. The % max values indicate the mean 6 SEM percentage inhibition of basal GIRK currents by a drug at the highest concentrations
tested. The highest concentrations tested (mM) and the number of oocytes tested (n) are shown in parentheses. The nH values indicate the mean 6 SEM of Hill
coefficients. ND indicates that the value was not determined because of a low effectiveness of the drug.
doi:10.1371/journal.pone.0028208.t001
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and duloxetine exist mainly in a protonated form, approximately
96.9% and 98.9% at pH 7.4, respectively, and the proportion of
the uncharged form increases with an increase in pH. We
examined whether changes in extracellular pH would affect GIRK
channel inhibition by sertraline or duloxetine. However, in oocytes
that expressed GIRK1/2 channels, the percentage inhibition of
GIRK channels by sertraline or duloxetine at the same
concentrations was not significantly affected by extracellular
pH 7.4 and 9.0 (no significant pH6drug interaction, P.0.05,
two-way ANOVA; P.0.05 at each concentration, Tukey-Kramer
post hoc test; Fig. 4). The results indicate that a marked increase in
the proportion of the uncharged form of sertraline and duloxetine
may not significantly affect all of the inhibitory effects on GIRK
channels, suggesting that GIRK channel inhibition may be
mediated by both forms of the drugs with similar effectiveness.
Additionally, the inhibition by the antidepressants was unlikely
mediated by nonspecific membrane perturbation induced by the
uncharged form.
Effects of sertraline on GIRK channels activated by GTPcS,
a nonhydrolyzable GTP
GIRK channels are activated by various Gi/o-protein-coupled
receptors through the direct action of G-protein bc subunits
Figure 3. Characteristics of the inhibitory effects of sertraline and duloxetine on GIRK currents. (A) Representative GIRK1/2 currents
elicited by a voltage step to 2100 mV for 2 s from a holding potential of 0 mV in the presence or absence of 30 mM sertraline (left) or 30 mM
duloxetine (right) applied for 3 min. Current responses were recorded in an hK solution that contained 96 mM K
+. Arrows indicate the zero current
level. (B) Current-voltage relationships of the magnitudes of 3 mM Ba
2+-sensitive currents and the magnitudes of currents reduced by 30 mM
sertraline (left, n=9)or30mM duloxetine (right, n=6) in oocytes that expressed GIRK1/2 channels. Current responses were normalized to the 3 mM
Ba
2+-sensitive current component measured at a membrane potential of 2100 mV (1851.06220.4 nA, n=15). (C) Percentage inhibition of GIRK1/2
channels by 30 mM sertraline or 30 mM duloxetine over the voltage range of 2120 to 240 mV. The magnitudes of inhibition of GIRK currents by
30 mM sertraline (left, n=9) and duloxetine (right, n=6) at the end of the voltage pulses were compared with the 3 mM Ba
2+-sensitive current
components. All values are expressed as mean 6 SEM.
doi:10.1371/journal.pone.0028208.g003
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effects of sertraline on GIRK channels activated by G-protein-
coupled signaling mechanisms were further examined using
GTPcS, a nonhydrolyzable GTP analog that maintains G-
proteins in an activated state. Injection of GTPcS into Xenopus
oocytes injected with GIRK1 and GIRK2 mRNAs increased
inward currents with time and reached a steady-state level
(516.06123.7 nA, n=5) as reported previously [49,51]. The
increased inward currents were completely blocked by 3 mM Ba
2+,
whereas GTPcS injection into uninjected oocytes had no significant
effect on current responses to 3 mM Ba
2+ (3.962.1 nA, n=5).
Increased GIRK currents composed of basal GIRK currents and
GTPcS-induced GIRK currents were inhibited by sertraline
(IC25=5.560.7 mM; IC50=18.163.0 mM; nH=1.2460.09; n=5;
Fig. 5). The concentration response curve for the inhibition of total
GIRK currents by sertraline was partially different from that for the
inhibition of basal GIRK currents in GTPcS-untreated oocytes
injected with GIRK1 and GIRK2 mRNAs (P,0.05 at 30 mM,
Tukey-Kramer post hoc test, Fig. 5). The results suggest that the
potency of the inhibition of GIRK channels activated by GTPcS-
induced G-protein activation may be slightly higher than that of
basally active GIRK channels, although the maximal efficacy was
similar.
Sertraline inhibits ethanol-induced GIRK currents.
GIRK channels are also activated by ethanol independent of G-
protein signaling pathways [34]. Sertraline was shown to reduce
ethanol consumption in mice [52] and was effective in alcoholics
[53]. Therefore, we also examined the effects of sertraline on GIRK
channel activationinducedbyethanol. Theeffectsof sertraline were
evaluated by measuring the amplitude of the ethanol-induced
current response during the extracellular application of sertraline at
different concentrations. In oocytes injected with GIRK1 and
GIRK2 mRNAs, the GIRK currents induced by 100 mM ethanol
(344.2640.3 nA, n=6) were reversibly attenuated in the pre-
sence of sertraline (IC25=6.261.4 mM; IC50=29.665.5 mM;
nH=0.8760.17; n=6; Fig. 6A, 6B). However, the 100 mM
ethanol-induced GIRK currents were not significantly affected by
intracellularly applied sertraline (104.969.1% of untreated control
current, paired t-test, P.0.1, n=6; Fig. 6C). Moreover, in oocytes
that expressed GIRK channels, the basal currents were not sub-
stantially affected by intracellularly applied sertraline (92.561.6%
of untreated control current, n=6). The results indicate that
intracellular sertraline could not inhibit GIRK channels. In
contrast, GIRK channel inhibition induced by extracellularly
applied sertraline, which is mainly protonated at pH 7.4, was
reversible with washout (Figs. 1A and 6A). Because the protonated
form may not readily permeate the cell membrane, extracellularly
applied sertraline may exist mainly on the extracellular side.
Altogether, extracellular sertraline may inhibit GIRK channels
activated by ethanol. Additionally, the extent of inhibition by
sertraline of GIRK1/2 channels activated by ethanol was higher at
100 and 300 mM than that of basally active GIRK1/2 channels by
G-proteins (P,0.05, Tukey-Kramer post hoc test), indicating a
significant difference in the maximal efficacy of sertraline between
ethanol activation of GIRK channels and G-protein activation of
the channels.
Figure 4. Concentration-dependent inhibition of GIRK channels by sertraline or duloxetine at different pH values. The magnitudes of
inhibition of GIRK currents by the antidepressants were compared with the 3 mM Ba
2+-sensitive current components in oocytes that expressed
GIRK1/2 channels (1020.8696.2 nA at pH 7.4, n=16 for sertraline and n=7 for duloxetine; 1079.56173.8 nA at pH 9.0, n=7 for sertraline and n=6
for duloxetine, respectively). Current responses were measured at a membrane potential of 270 mV in an hK solution that contained 96 mM K
+. Each
point and error bar represent the mean 6 SEM of the percentage responses.
doi:10.1371/journal.pone.0028208.g004
Figure 5. Effects of sertraline on total GIRK currents composed
of GTPcS-induced and basal GIRK currents. For comparison, the
effects on GTPcS-untreated basal GIRK currents shown in Figure 2 are
also shown. The magnitudes of inhibition of GIRK currents by sertraline
were compared with the 3 mM Ba
2+-sensitive current components.
Each point and error bar represent the mean 6 SEM of the percentage
responses (n=5 for GTPcS-injected oocytes and n=16 for GTPcS-
untreated oocytes). Current responses were measured at a membrane
potential of 270 mV in an hK solution that contained 96 mM K
+.
doi:10.1371/journal.pone.0028208.g005
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The present study demonstrated that the SSRI sertraline, SNRI
duloxetine, and second-generation TCA amoxapine effectively
inhibited brain-type GIRK1/2 channels and cardiac-type
GIRK1/4 channels expressed in Xenopus oocytes. However, the
5-HT2 receptor antagonist nefazodone, SNRI venlafaxine, and
NaSSAs mianserin and mirtazapine weakly inhibited both types of
GIRK channels even at high concentrations. The inhibitions by
different classes of antidepressants were concentration-dependent
with various degrees of potency and effectiveness. In contrast,
Kir2.1 channels in other Kir channel subfamilies were insensitive
to all of the drugs. Furthermore, the present results suggest that
sertraline and duloxetine primarily inhibited GIRK channels at
the holding potential of 0 mV before the voltage pulses. The
effects of sertraline on GIRK channels were voltage-independent
and time-independent during each voltage pulse, similar to the
effects of various TCAs [42]. The effects of duloxetine decreased
voltage-dependently with negative membrane potentials and time-
dependently up to a steady current level in each voltage pulse, and
the voltage-dependency was associated with a time-dependent
decrease in the inhibition by duloxetine at more negative
membrane potentials. The present results also suggest that the
site of action on the channels may be extracellular. In contrast,
blockade of GIRK channels by extracellular Ba
2+ and Cs
+, which
occlude the pore of the open channel, increases concentration-
dependently, voltage-dependently with negative membrane potentials,
and time-dependently with a comparatively small effect on the
instantaneous current but marked inhibition on the steady-state
current at the end of the voltage pulses [27]. These observations
suggest that sertraline and duloxetine may cause an allosteric
conformational change in GIRK channels, rather than simple
occlusion of the open channel. Additionally, sertraline may stably
bind to the channels during the voltage pulses, whereas duloxetine
may partially dissociate from the channels in the voltage pulses. The
nH values obtained from the concentration-response relationships
for sertraline and duloxetine were almost 1 (Table 1), suggesting an
one-to-one interaction between the drug and the binding site.
Interestingly, GIRK channels were significantly inhibited by the
SSRI sertraline and SNRI duloxetine, despite a great difference in
the pharmacological profiles for monoamine transporters. The
chemical structure of sertraline is distinct from that of duloxetine
[2,54]. These antidepressants may act at different binding sites on
the channels, and agents with similar structures may interact with
GIRK channels. However, the SNRIs venlafaxine and milnacipran
[43] had weak or little effects on GIRK channels, respectively. The
distinctive effects of the SNRIs on GIRK channels may be attribute
to their diverse chemical structures [54]. The Xenopus oocyte
expression system is useful to determine drug actions on membrane
proteins, such as voltage-gated Na
+ and Ca
2+ channels, glutamate
receptor channels, 5HT1C receptor [55]. Since neuronal and
cardiac GIRK channels are considered to consist predominantly
of GIRK1/2 channels and GIRK1/4 channels, respectively
[26,29,36], the effects of antidepressants on GIRK1/2 and
Figure 6. Effect of sertraline on ethanol-induced GIRK currents. (A) Current responses to 100 mM ethanol (EtOH), 100 mM EtOH in the
presence of 30 mM sertraline, and 100 mM EtOH in an oocyte injected with GIRK1 and GIRK2 mRNAs. Asterisk indicates the zero current level. Bars
show the duration of application. (B) Concentration-dependent inhibition of EtOH-induced GIRK currents by sertraline. Icontrol is the amplitude of GIRK
currents induced by 100 mM EtOH (344.2640.3 nA, n=6), and I is the current amplitude in the presence of sertraline. (C) Lack of effect of intracellular
sertraline on 100 mM EtOH-induced GIRK currents. The amplitude of EtOH-induced GIRK currents after sertraline injection (black bar) was compared
with EtOH-induced GIRK currents before the injection (control, white bar) in the same oocyte that expressed GIRK channels (n=5). Current responses
were measured at a membrane potential of 270 mV in an hK solution that contained 96 mM K
+. All values are expressed as mean 6 SEM.
doi:10.1371/journal.pone.0028208.g006
GIRK Channel Inhibition by Antidepressants
PLoS ONE | www.plosone.org 7 December 2011 | Volume 6 | Issue 12 | e28208GIRK1/4 channels expressed in Xenopus oocytes were investigated
in the present study. However, GIRK subunits have been suggested
to form functional GIRK channels composed of several types of
tetrameric stoichimetries in various cell populations, particularly
neurons [56]. GIRK1 subunits are posttranslationally modified by
glycosylation [26,56,57]. Furthermore, GIRK channels are regu-
lated by not only G proteins but also phosphatidylinositol 4,5-
bisphosphate in the cell membrane, polyamines and protein kinases
[33]. The effects of antidepressants on GIRK channels might be
influenced by differences in composition of the channel subunits,
levels of glycosylation of GIRK1 subunits, and interaction with
membrane and intracellular factors between the Xennopus oocyte
expression system and neurons. Further studies using neurons and
cardiac myocytes may be useful for advancing our understanding of
the effects of antidepressants on GIRK channels.
The therapeutic serum concentrations range from approxi-
mately 0.16 to 0.82 mM for sertraline, 0.07 to 0.27 mMf o r
duloxetine, 0.57 to 1.9 mM for amoxapine, 0.02 to 0.64 mMf o r
nefazodone, 0.06 to 0.26 mM for mianserin, 0.08 to 0.37 mMf o r
mirtazapine, and 0.72 to 1.44 mM for venlafaxine [2,58–60].
Additionally, increases in antidepressant doses are associated with
increases in blood concentrations [59]. The concentrations in
cases of overdose were reported to reach up to 13.7 mMf o r
sertraline [61], 8.4 mM for duloxetine [62], 57.4 mMf o r
amoxapine [63], 11.7 mM for nefazodone, 18.9 mM for mianserin
[59], 8.7 mM for mirtazapine [64], and 302.8 mM for venlafaxine
[65]. Most of the doses of antidepressants are distributed in
various tissues from the blood, and antidepressants generally
accumulate in the brain [2,58,66]. Indeed, brain levels of
antidepressants were 40-fold higher for sertraline [67], 15-fold
higher for duloxetine [68], 8.7- to 35.5-fold higher for amoxapine
[69], 1.3- to 1.8-fold higher for nefazodone [70], 12.1-fold higher
for mianserin [71], 3.2-fold higher for mirtazapine, and 4.9-fold
higher for venlafaxine [66] compared with blood levels.
Altogether, due to the high brain-to-blood partition ratios,
presumed brain concentrations during treatment with therapeutic
doses would range from approximately 6.4 to 32.8 mMf o r
sertraline and 5.0 to 67.5 mM for amoxapine, and those after
overdose would reach up to 548 mMf o rs e r t r a l i n e ,1 2 6mMf o r
duloxetine, 499 or 2038 mM for amoxapine, 229 mMf o r
mianserin, and 1484 mM for venlafaxine. In addition, it has
been shown that the therapeutic concentrations of some SSRIs in
the brain were much higher than binding affinities of the
antidepressants to monoamine transportors [72–75]. Brain
concentrations at therapeutic doses of sertraline and amoxapine
and after overdose of sertraline, duloxetine, amoxapine, mian-
serin and venlafaxine overlap with their effective concentrations
in inhibiting predominant brain-type GIRK1/2 channels (Fig. 2).
Therefore, the present results suggest that some inhibition of
GIRK channels in the brain might occur with the antidepressant
medication, particularly sertraline. However, mirtazapine and
nefazodone may have small or little effects on GIRK channels
even at toxic levels. Inhibition of GIRK channels causes a
depolarization of membrane potential, resulting in an increase in
cell excitability [38]. GIRK channels play an important role in
regulating neuronal excitability and synaptic transmission
[36,41]. Therefore, even partial inhibition of GIRK channels
by the antidepressants may affect various brain functions.
Interestingly, GIRK2 knockout mice exhibit reduced anxiety-
related behavior [76]. Animal studies have shown that sertraline
has anxiolytic properties [77,78]. Indeed sertraline is clinically
effective in the treatment of panic disorder and posttraumatic
stress disorder [79]. Although the therapeutic effects are generally
thought to be primarily attributable to inhibition of serotonin
reuptake in the brain [2], some inhibition of GIRK channels
might also contribute to improvement of anxiety symptoms.
Although the risk of seizures with antidepressants is generally
very low, the association with overdose is well established [80].
However, the molecular mechanisms by which antidepressants
cause seizures have not been clarified. GIRK2 knockout mice
exhibit spontaneous seizures and are more susceptible to seizures
induced by pentylenetetrazol than wild-type mice [37]. The risk of
seizures in overdoses with sertraline, duloxetine, mianserin, and
venlafaxine significantly increases [80–82], and amoxapine
overdose is more likely to cause seizures [83]. Brain levels of the
drugs in overdose cases may be considerably higher than levels
during treatment at therapeutic doses, suggesting significant
inhibition of neuronal GIRK channels by the drugs. Additionally,
other types of K
+ channels are inhibited by antidepressants at
micromolar concentrations, that is, the two-pore-domain K
+
channel, TREK-1 for sertraline and voltage-gated K
+ channels for
amoxapine and mianserin [16,17,21]. Therefore, the inhibition of
GIRK channels by the drugs after overdose together with the
different types of K
+ channels may contribute to increased seizure
activity and the occurrence of other neurological side effects by
increasing neuronal excitability.
In the heart, GIRK channels cause a slowing of heart rate in
response to activation of M2 muscarinic receptors through
acetylcholine release from the stimulated vagus nerve [25,26].
GIRK1 and GIRK4 knockout mice exhibit slightly elevated
resting heart rates [39]. The present results indicate that sertraline,
duloxetine, amoxapine, and venlafaxine can partially inhibit
cardiac-type GIRK1/4 channels at blood levels after overdose,
although the corresponding heart concentrations were not
determined. These antidepressants are associated with sinus
tachycardia in cases of toxicity after overdose [81,82,84,85]. In
addition, the drugs exhibit low micromolar binding affinities for
the muscarinic receptor, with the exception of venlafaxine [2,86],
and nanomolar to low micromolar binding affinities for norepi-
nephrine transporters [2,68]. Altogether, sinus tachycardia
associated with drug overdose may be related to partial inhibition
of atrial GIRK channels as well as antagonism of the muscarinic
receptor and enhancement of sympathetic nerve activity.
Sertraline was shown to be effective in the treatment of
alcoholics [53]. Interestingly, GIRK2 knockout mice show
reduced ethanol-induced conditioned taste aversion and condi-
tioned place preference and are less sensitive than wild-types to
some of the acute effects of ethanol, including anxiolysis,
habituated locomotor stimulation, and acute handling-induced
convulsions [76,87]. In the present study, sertraline inhibited
ethanol-induced GIRK1/2 currents. Sertraline may suppress
some of the GIRK-related effects of ethanol. Furthermore, GIRK
knockout mice show an attenuation of the morphine withdrawal
syndrome [88]. Sertraline reduced the severity of the naloxone-
precipitated opioid withdrawal syndrome in rats [89]. GIRK
knockout mice also show reduced cocaine self-administration [90].
Inhibition of GIRK channels by sertraline may play a role in the
treatment of addiction to these drugs.
Supporting Information
Figure S1 Effect of sertraline on outward GIRK cur-
rents. In a Xenopus oocyte injected with GIRK1 and
GIRK2 mRNAs, current responses to 30 mM sertraline
and 3 mM Ba
2+ at a membrane potential of 210 mV in a
K4 solution that contained 4 mM K
+ are shown. Asterisk
indicates the zero current level.
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